Analysts Set Tyra Biosciences, Inc. (NASDAQ:TYRA) Target Price at $30.83

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) has earned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have covered the stock in the last year is $30.83.

A number of equities analysts recently issued reports on the company. Piper Sandler assumed coverage on Tyra Biosciences in a report on Wednesday, May 21st. They issued an "overweight" rating and a $33.00 target price on the stock. Wedbush reaffirmed an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, March 28th. Finally, HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st.

Institutional Trading of Tyra Biosciences

Large investors have recently modified their holdings of the business. KLP Kapitalforvaltning AS bought a new stake in Tyra Biosciences in the 4th quarter worth approximately $31,000. US Bancorp DE purchased a new position in Tyra Biosciences in the 4th quarter worth approximately $50,000. BNP Paribas Financial Markets purchased a new position in shares of Tyra Biosciences during the fourth quarter valued at approximately $60,000. Aquatic Capital Management LLC purchased a new position in shares of Tyra Biosciences during the fourth quarter valued at approximately $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Tyra Biosciences during the first quarter valued at approximately $84,000. Institutional investors own 84.14% of the company's stock.

Tyra Biosciences Stock Performance

Shares of NASDAQ:TYRA traded up $0.38 during midday trading on Friday, hitting $10.55. 194,217 shares of the stock were exchanged, compared to its average volume of 271,731. The stock has a market capitalization of $560.10 million, a price-to-earnings ratio of -6.55 and a beta of 1.07. The business's 50-day moving average price is $9.31 and its 200 day moving average price is $12.17. Tyra Biosciences has a 12 month low of $6.42 and a 12 month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. As a group, sell-side analysts expect that Tyra Biosciences will post -1.57 EPS for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.